Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Chf Trials > Hf Trials > Flashcards

Hf Trials Flashcards

1
Q

A-HEFT (2004)

A

Hydral 37.5+Isordil 20 TID

  • CIII/IV Black Pts
  • Improved mortality, Hosp, QOL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Ascend-HF (2011)

A

Nesiritide

  • ADHF, Acute HF, severe HF
  • dyspnea better at 6h+24h, but not combined
  • NO DIFF in 30day HF readmit
  • NO DIFF in ARF or Death
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ATLAS

A

Low vs High Dose ACE

  • NYHA II-IV, EF <30%
  • decreased mortal TREND
  • Lower Overall Death+Hosp
  • Lower Admission
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CAPRICORN (2001)

A

COREG post-MI w/LV dysfunction
EF<40%
- Decreased all cause mortal of Admission for CV
- CV mortality, nonfatal MI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CARRESS-HF (2012)

A

UF in DHF w/cardiorenal syndrom

  • ADHF, increase Cr+Volume, comp to Diuresis
  • Worse 2/2 inc Cr, no diff in weight, more AE (bleed, ARF)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

CASTLE-AF (2018)

A

Catheter Ablation for AF+HF

  • RCT, failed Anti-arrth.
  • Composite outcome Death/HF hosp better, death alone half
  • Mostlcy CII, persistent AF (vs parox AF)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CHARM (2003)

  • Preserved
  • Alternative
  • Added
A

Candesartan
Preserved - No diff in death, less admisison
Alternative - Intolerant pts, less death+adm together+indiv
Added - Less Death+Adm together+indiv

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

CHF-STAT (1995)

A

Amio in CHF+asymptomatic Vent Arrythmia

  • Dilated LV+low ef
  • No diff in survival, trend to lower mortal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q 
CIBIS (1994)
CIBIS II (1999)
CIBIS III (2005)
A 
Bisoprolol+EF<40%
-Class III+IV on ace+diuretic
- No diff in sudden deaht, less hosp, improved sx
Bis EF<35%
- Mortality benefit
Bisoprolol first vs Enalapril First
- Noninferiority w/bisop first
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

COMET (2003)

A

Coreg vs Metop Tartrate European

  • C II-Iv, prev CV admit, EF <35% on ACE+diuretic
  • Decreased mortal, similar admit
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

CONSENSUS (1987)

A

Enalapril on CIV

  • Mortal RRR 40%, 1yr 31%
  • Decrease HF progression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

COPERNICUS (2002)

A

Coreg on EF<25%, CIII-IV

  • Coreg 25 bid
  • Reduced Death_Hosp for CV cause and HF cause
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

CORONA (2007)

A

Crestor in rEF, CII-IV

- No reduced survival, poss reduced Hosp

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

DIG trial (1997)

A

Dig on M&M of HFrEF

  • No mortal diff
  • Fewer Hosp
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

EMPHASIS (2011)

A

Eplerenone HfrEF +MILD sx

- Dec death from CV or adm for HF, dec total mortal, dec hospitalization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

EPHESUS (2003)

A

Eplerenone POST-MI

  • Dec comp death, hosp for HF, AMI, CVA, VT/VF
  • Dec SCD
  • Inc hyperkal (5.5 vs 4%)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

FAIR-HF (2009)

A

Ferric Carboxymaltose in HF+FE def

  • CII or CII, EF<40%, Fe def+anemia
  • Pt assessment better, improved NYHA class, 6MWT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

I-PRESERVE (2008)

A

Irbesartan in PRESERVED EF

  • NYHA II-IV
  • No diff in death or hosp rates
19
Q

MERIT-HF (1999)

A

Toprol HFrEF

  • C II-IV, target 200qd
  • RR 0.66, fewer Mortal, SCD, HF death
20
Q

NESIRITIDE (2000)

A

IV nes for DHF

- 6hr dec PCWP, reduced Dyspnea much more

21
Q

OPTIME-CHF (2002)

A

SHORT TERM Milrinone for ADHF

  • IIIor IV, adm w/HF not req Inotropy
  • 48h milrinone
  • No sig diff in LOS, inc hypotension, inc atrial arryhtm, no diff in-hosp mortal or death/readm
22
Q

PARADIGM-HF (2014)

A

ENTRESTO VS ENALAPRIL

  • CII-IV, EF <40%
  • Dec death or Hosp for HF, less symptoms
  • More HoTN+angioedema
  • Inc BNP, nt-probnp
  • excluded Hotn or HyperK pts
23
Q

PRAISE (1996)

A

Amlodipine in M&M for sev HF

  • CIII or IV, EF <30%
  • No change in death+hosp for cv
  • poss benefit in nonischemics
24
Q

PROMISE (1991)

A

Oral milrinone in Mortal for CHF

  • Pts on dig, diuretic, ACE
  • Increase in all cause, CV mortal, worse for CIV
  • More Hotn+syncope
25
Q

RALES (1999)

A 
Spirinolactone on M&amp;M for sHF
- CIII or IV, EF <35%, ace/diuretic/dig
- Dec death, dec prog HF+death from cardiac cause
- Dec freq of Hosp
Exclude Cr>2.5, K>5
26
Q

SAVE (1992)

A

CAPTOPRIL M&M LV dysf post-MI

  • CI, 3-16d post MI
  • More death, severe HF, recurrent MI in placebo
27
Q

SENIORS (2005)

A

Nebivolol

  • Elderly+HF, >70%
  • All cause mortal+CV admit decreased
  • No diff in death alone
28
Q

SOLV-D (1991)

A

Enalapril in EF<35% and CII-IV

  • Bigger gp than CONSENSUS
  • pts on conventional therapy, dig/diuretic/nitrate
  • reduced mortality 16%, risk of death 2/2 hf, reduced hosp
29
Q

SOLV-T (D?) (1991)

SOLV-P (1992

A

Treatment: Enalapril in CHF+EF<35%
- Inc survival, dec hosp, dec progression for HF
Prevention: Enalapril Asymptom+low EF
- Death Equal, less hosp for HF, less death+hosp for HF

30
Q

UNLOAD (2007)

A

UF vs IV diuretics ADHF

- more wt dec, dysp scores similar, 90d less readmit for HF

31
Q

US- Carvedilol (1996)

A

Carved on M&M of HF

  • EF<35%
  • Dec death, dec hosp, dec combo
32
Q

V-HEFT 1 (1986)
V-HEFT 2 (1991)
- Vasodilator study on Vets/MEN

A
  1. Vasodilator on Mortal in CHF, chronic
    - No benefit for Prazosin
    - Benefit for Hydral/Isosorbite on death+EF
  2. Enalapril vs Isordil
    - Enalapril better mortal, both inc ef, Isordil inc ET too
33
Q

Val-HEFT (2001)

A

Valsartan v Placebo

  • CII, III, IV
  • Combined dec mortal, HF adm, inotropy/vasodilator
  • Driven by Dec HF adm, also in NYHA, adverse effects if on ACE+BB
34
Q

VALIANT (2003)

A

Valsartan, Captopril, or both in MI+HF+rEF

  • .5-10d post MI
  • Non-signif diff in all 3 groups, ACE/ARB group had Most side effects
35
Q

WARCEF (2012)

A

Warfarin vs ASA in HF+Sinus Rhythm

  • Time to isch stroke, ICH, death
  • Coumadin INR 2-3.5 vs asa 325
  • No difference. Less stroke in coumadin, more major hemorrhage
36
Q

Ambition trial

A

Ph

37
Q

Tread hf

A

Stopping hf meds

Worsen ef

38
Q

Us carvedilol

A

Coreg higher doses weight?

39
Q

DAPA-HF

A

Dapaglifozin in hfref

  • dapglif sglt2 in hf, only 45% w t2dm
  • early separation of all cause mortal and hf hosp
  • equal in dm and no dm!!
40
Q

Chf af

A

Amio for chf
No diff in rate v rhythm control
High rates of amio rather than ablation
- thats why castle af different

41
Q

Ropa-Dope

A

Renal dose dopamine

  • no utility in hf
  • no improved renal function
42
Q

Caress- hf

A

acute decompensated HF and cardiorenal syndrome, ultrafiltration is associated with more adverse events, worsening renal function, and no change in weight when compared to medical therapy.

43
Q

Optime - hf

A 
Iv milrinone decompensated hf without shock
No sig diff milrinon v placebo
No inhospital mortality diff
More hypotension and atrial arrythmia
Post hoc
Icm worse nicm better
44
Q

Everest

A

Tolvaptan 15mg
Diuresis of free water in hyponatremic patients
Increase lfts outpatient after 30 days

Chf Trials (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions